Obstructive Hypertrophic Cardiomyopathy Clinical Trial
Official title:
A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.
This is a randomized, double-blinded, placebo-controlled clinical study witha long-term extension to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM. Approximately 81eligible participants will be enrolled and randomized in a 2:1 ratio (mavacamten:placebo). Participants will receive mavacamten or matching placebofor 30 weeks indouble-blinded manner. After 30-week double-blinded placebo-controlled treatment, eligible participants will receive mavacamten for additional 48 weeks (placebogroup: switch from placebo to mavacamten, mavacamten group: maintain on mavacamten). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06023186 -
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
|
||
Completed |
NCT05726799 -
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
|
||
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
Active, not recruiting |
NCT06211595 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Recruiting |
NCT06116968 -
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
|
Phase 3 | |
Completed |
NCT03470545 -
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 | |
Recruiting |
NCT05879523 -
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
|
Phase 1 | |
Not yet recruiting |
NCT06146660 -
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT05771987 -
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
|
N/A | |
Recruiting |
NCT06224621 -
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
|
N/A | |
Completed |
NCT01631006 -
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT06368037 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Recruiting |
NCT05489705 -
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
|
||
Completed |
NCT06354556 -
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04783766 -
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
|
Phase 1 |